Employees: 247
Size Revenio (REG1V.HE) is a Finland Health Care company (Medical Specialties) with a market value of $428M, the 53rd largest of 65 Finland companies the cockpit tracks. Shares closed at €9.29 on 18 Nov 2026.
Performance Over six months the shares fell 34.5%, against -16.2% for the median peer and -9.7% for the Finland market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 43.7% over the last twelve months (peer median +3.9%); the operating margin is 10.4% (peer median 3.2%).
Valuation It trades at 17.1× forward earnings against a peer median of 13.2× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.3 points below its cost of capital (6.6% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €157M | €110M | €104M | €96.6M | €97.0M |
| Revenue growth | — | +6% | +7% | 0% | — |
| Gross profit | €52.6M | €46.9M | €44.7M | €45.2M | €47.0M |
| EBITDA | €24.1M | €29.7M | €29.9M | €30.1M | €32.9M |
| Net income | €12.0M | €17.4M | €18.5M | €19.1M | €21.8M |
| Free cash flow | €15.0M | €29.1M | €22.7M | €10.2M | €22.1M |
| Capital expenditure | €4.78M | €4.18M | €4.17M | €4.08M | €2.00M |
| Total debt | €253M | €11.0M | €12.8M | €17.3M | €19.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REG1V.HE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -9.3% | 4th lowest of 21 |
| 6-month return | -34.5% | -16.2% | 2nd lowest of 21 |
| Distance from 52-week high | -60.3% | -40.7% | lowest of 21 |
| Revenue growth (TTM) | +43.7% | +3.9% | 6th highest of 20 |
| Operating margin | 10.4% | 3.2% | 7th highest of 20 |
| Forward P/E | 17.1× | 13.2× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 18.5% | 10.3% | 5th most demanding of 11 |
| Growth delivered (Del g) | +12.4% | +3.9% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | +6.0 pp | +4.8 pp | 5th most demanding of 11 |
| ROIC minus cost of capital | -3.3 pp | -2.2 pp | 8th lowest of 17 |
| EV / EBITDA | 26.0× | n/a | — |
| Net debt / EBITDA | 9.8× | -1.3× | most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Revenio REG1V.HE | Finland | $428M | -34% | +44% | 10% | 17.1× | 18.5% | +12.4% |
| China Isotope & Radiation 1763.HK | Hong Kong | $428M | -41% | -5% | 13% | 6.0× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $425M | -16% | +10% | 27% | 13.2× | -0.1% | +15.6% |
| Shoulder Innovations SI | United States | $432M | +39% | +55% | -54% | n/a | n/a | n/a |
| Mobia Medical MOBI | United States | $434M | +2% | +105% | -145% | n/a | n/a | n/a |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $436M | +39% | +5% | 11% | 35.7× | 20.6% | +2.2% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | n/a | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $440M | -16% | -3% | 6% | n/a | 5.8% | +0.3% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | n/a | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 10% | n/a | -1.0% | -2.8% |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 19.8× | 9.6% | +5.6% |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 3% | n/a | 21.5% | -11.7% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 8.4× | n/a | n/a |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | n/a | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | n/a | 36.0% | -6.9% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | n/a | n/a | n/a |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | n/a | 41.7% | +15.9% |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | n/a | 10.9% | +11.0% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |